Phathom Pharmaceuticals, Inc. (PHAT)
Automate Your Wheel Strategy on PHAT
With Tiblio's Option Bot, you can configure your own wheel strategy including PHAT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PHAT
- Rev/Share 1.1374
- Book/Share -4.7017
- PB -2.3183
- Debt/Equity -0.6016
- CurrentRatio 3.5782
- ROIC -1.3007
- MktCap 760973690.0
- FreeCF/Share -3.9275
- PFCF -2.6922
- PE -3.1195
- Debt/Assets 0.6919
- DivYield 0
- ROE 0.9931
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PHAT | Cantor Fitzgerald | -- | Overweight | -- | $23 | Feb. 14, 2025 |
News
Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy
Published: June 10, 2025 by: Seeking Alpha
Sentiment: Positive
I'm bullish on Phathom Pharmaceuticals, Inc. after the FDA granted 10-year exclusivity to their flagship GI drug, Voquezna, giving them near-monopoly status. For those who don't know, this is a big deal because the FDA doesn't grant exclusivity rights often. Voquezna's prescription growth is surging, now with 390,000 fills and 127,000 in Q1 2025 alone, which is driving strong revenue momentum.
Read More
Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 107.4% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom's Citizen Petition filed on December 11, 2024 and communicated the Agency's intention to correct the Orange Book to recognize the proper 10 years of New Chemical Entity exclusivity for VOQUEZNA® (vonoprazan) tablets, extending through May 3, 2032.
Read More
After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT)
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
Phathom Pharmaceuticals (PHAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Read More
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript
Read More
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.42 per share a year ago.
Read More
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providers Net revenues of $28.5 million reported for Q1 Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwinds Strategic cost reductions and executive leadership changes implemented to support sustainable revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026 Management to host conference call today, May 1, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J.
Read More
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
FLORHAM PARK, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the company will present real-world data for its first-in-class treatment VOQUEZNA® (vonoprazan) at Digestive Disease Week® (DDW) being held May 3–6, 2025, in San Diego, CA. VOQUEZNA is the first and only treatment of its kind approved by the U.S. Food and Drug Administration for use in adults for the relief of heartburn associated with Non-Erosive GERD and for the treatment of all severities of Erosive Esophagitis (EE), commonly …
Read More
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
FLORHAM PARK, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8th, 2025, at 10:15 am ET.
Read More
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, March 6, 2025, to report its fourth quarter and full year 2024 financial results and provide a business update.
Read More
About Phathom Pharmaceuticals, Inc. (PHAT)
- IPO Date 2019-10-25
- Website https://www.phathompharma.com
- Industry Biotechnology
- CEO Mr. Steven L. Basta M.B.A.
- Employees 427